FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039602013> ?p ?o ?g. }

• W2039602013 endingPage "22" @default.
• W2039602013 startingPage "22" @default.
• W2039602013 abstract "Abstract Background: Up to 75% of advanced breast cancer patients develop bone metastases (BM) that induce increased osteoclast activity resulting in local bone destruction. The ensuing skeletal complications, including fractures, may have serious consequences. Denosumab, a fully human monoclonal antibody, inhibits RANKL, a key mediator of osteoclast activity. Denosumab has been shown to increase bone mineral density and reduce fractures in postmenopausal women with low bone mass. Primary results from a recently completed randomized pivotal study demonstrated that denosumab was superior to zoledronic acid (ZA) in delaying and preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. Here, we describe results of other endpoints from the study.Methods: Patients with breast cancer and BM (N=2046) who had not been treated with intravenous (IV) bisphosphonates were randomized 1:1 to receive either subcutaneous (SC) denosumab 120 mg and IV placebo, or SC placebo and IV ZA 4 mg every 4 weeks. All patients were encouraged to take daily supplemental calcium (≥500 mg) and vitamin D (≥400 IU). The primary endpoint was time to first on-study SRE (predefined as pathologic fracture, radiation to bone, surgery to bone, or spinal cord compression). Other endpoints included time to first radiation of bone; time to first on-study SRE or hypercalcemia of malignancy (HCM); skeletal morbidity rate (SMR; the number of SREs per year); and the proportion of patients with at least 1 on-study SRE. SMR was defined as the ratio of the number of SREs, allowing for one event every 21 days, divided by the patient's time at risk.Results: As previously reported, denosumab was superior to ZA in significantly delaying the time to first on-study SRE (hazard ratio [HR] 0.82; 95% CI: 0.71, 0.95; P&lt;0.0001 noninferiority; P=0.01 superiority) and the time to first and subsequent on-study SRE (rate ratio 0.77; 95%CI: 0.66, 0.89; P=0.001). Denosumab also significantly delayed the time to first radiation to bone (HR 0.74; 95% CI: 0.59, 0.94; P=0.01) and the time to first on-study SRE or HCM (HR 0.82; 95% CI: 0.70, 0.95; P=0.007) compared with ZA. Denosumab reduced the mean SMR compared with ZA (0.45 vs 0.58, respectively; P=0.004). The total number of SREs was 491 events for denosumab and 623 events for ZA. At the primary data analysis cut-off date (study duration: 34 months), the proportion of patients (95% CI) experiencing at least 1 on-study SRE was lower in the denosumab arm (30.7% [27.9%, 33.5%]) than the ZA arm (36.5% [33.5%, 39.4%]). Overall, the incidence of adverse events (AEs) and serious AEs was consistent with what has been previously reported for these two agents. AEs potentially associated with acute phase reactions during the first 3 days of study were reported in 10% of the denosumab arm and 27% of the ZA arm.Conclusion: Denosumab was more efficacious than ZA in delaying time to first radiation to bone and first on-study SRE or HCM and in reducing skeletal morbidity (SMR) and the proportion of patients with an SRE. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 22." @default.
• W2039602013 created "2016-06-24" @default.
• W2039602013 creator A5009941371 @default.
• W2039602013 creator A5014687335 @default.
• W2039602013 creator A5022422153 @default.
• W2039602013 creator A5022815895 @default.
• W2039602013 creator A5034878356 @default.
• W2039602013 creator A5042317118 @default.
• W2039602013 creator A5043471689 @default.
• W2039602013 creator A5058474941 @default.
• W2039602013 creator A5065150967 @default.
• W2039602013 creator A5070594128 @default.
• W2039602013 creator A5074166211 @default.
• W2039602013 date "2009-12-01" @default.
• W2039602013 modified "2023-10-16" @default.
• W2039602013 title "A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases." @default.
• W2039602013 doi "https://doi.org/10.1158/0008-5472.sabcs-09-22" @default.
• W2039602013 hasPublicationYear "2009" @default.
• W2039602013 type Work @default.
• W2039602013 sameAs 2039602013 @default.
• W2039602013 citedByCount "14" @default.
• W2039602013 countsByYear W20396020132012 @default.
• W2039602013 countsByYear W20396020132013 @default.
• W2039602013 crossrefType "journal-article" @default.
• W2039602013 hasAuthorship W2039602013A5009941371 @default.
• W2039602013 hasAuthorship W2039602013A5014687335 @default.
• W2039602013 hasAuthorship W2039602013A5022422153 @default.
• W2039602013 hasAuthorship W2039602013A5022815895 @default.
• W2039602013 hasAuthorship W2039602013A5034878356 @default.
• W2039602013 hasAuthorship W2039602013A5042317118 @default.
• W2039602013 hasAuthorship W2039602013A5043471689 @default.
• W2039602013 hasAuthorship W2039602013A5058474941 @default.
• W2039602013 hasAuthorship W2039602013A5065150967 @default.
• W2039602013 hasAuthorship W2039602013A5070594128 @default.
• W2039602013 hasAuthorship W2039602013A5074166211 @default.
• W2039602013 hasConcept C118552586 @default.
• W2039602013 hasConcept C121608353 @default.
• W2039602013 hasConcept C126322002 @default.
• W2039602013 hasConcept C126894567 @default.
• W2039602013 hasConcept C141071460 @default.
• W2039602013 hasConcept C143998085 @default.
• W2039602013 hasConcept C168563851 @default.
• W2039602013 hasConcept C170493617 @default.
• W2039602013 hasConcept C203092338 @default.
• W2039602013 hasConcept C2776033226 @default.
• W2039602013 hasConcept C2776286101 @default.
• W2039602013 hasConcept C2776326535 @default.
• W2039602013 hasConcept C2776541429 @default.
• W2039602013 hasConcept C2776886416 @default.
• W2039602013 hasConcept C2777251235 @default.
• W2039602013 hasConcept C2778231337 @default.
• W2039602013 hasConcept C2780775167 @default.
• W2039602013 hasConcept C530470458 @default.
• W2039602013 hasConcept C71924100 @default.
• W2039602013 hasConceptScore W2039602013C118552586 @default.
• W2039602013 hasConceptScore W2039602013C121608353 @default.
• W2039602013 hasConceptScore W2039602013C126322002 @default.
• W2039602013 hasConceptScore W2039602013C126894567 @default.
• W2039602013 hasConceptScore W2039602013C141071460 @default.
• W2039602013 hasConceptScore W2039602013C143998085 @default.
• W2039602013 hasConceptScore W2039602013C168563851 @default.
• W2039602013 hasConceptScore W2039602013C170493617 @default.
• W2039602013 hasConceptScore W2039602013C203092338 @default.
• W2039602013 hasConceptScore W2039602013C2776033226 @default.
• W2039602013 hasConceptScore W2039602013C2776286101 @default.
• W2039602013 hasConceptScore W2039602013C2776326535 @default.
• W2039602013 hasConceptScore W2039602013C2776541429 @default.
• W2039602013 hasConceptScore W2039602013C2776886416 @default.
• W2039602013 hasConceptScore W2039602013C2777251235 @default.
• W2039602013 hasConceptScore W2039602013C2778231337 @default.
• W2039602013 hasConceptScore W2039602013C2780775167 @default.
• W2039602013 hasConceptScore W2039602013C530470458 @default.
• W2039602013 hasConceptScore W2039602013C71924100 @default.
• W2039602013 hasIssue "24_Supplement" @default.
• W2039602013 hasLocation W20396020131 @default.
• W2039602013 hasOpenAccess W2039602013 @default.
• W2039602013 hasPrimaryLocation W20396020131 @default.
• W2039602013 hasRelatedWork W1222286569 @default.
• W2039602013 hasRelatedWork W126584692 @default.
• W2039602013 hasRelatedWork W175716828 @default.
• W2039602013 hasRelatedWork W1974283015 @default.
• W2039602013 hasRelatedWork W2014794813 @default.
• W2039602013 hasRelatedWork W2019647842 @default.
• W2039602013 hasRelatedWork W2039602013 @default.
• W2039602013 hasRelatedWork W2056480857 @default.
• W2039602013 hasRelatedWork W2998688002 @default.
• W2039602013 hasRelatedWork W2773216875 @default.
• W2039602013 hasVolume "69" @default.
• W2039602013 isParatext "false" @default.
• W2039602013 isRetracted "false" @default.
• W2039602013 magId "2039602013" @default.
• W2039602013 workType "article" @default.